RxDoctor Payments Data

Bassam Hajjar, MD

Gastroenterology · Clifton, NJNPI 1316024946

Payments from drug & device makers

$5,418in general payments, 2019–2025

Across 228 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$957
  • AstraZeneca$599
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$544
  • Amgen$458
  • Aimmune Therapeutics, Inc.$331
  • Madrigal Pharmaceuticals$310
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,411100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,418 in reported general payments places this provider in the 70th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$385,680
Medicare patients
481
Services billed
4,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide220$203,272
IbsrelaTenapanor Hcl27$84,120
EliquisApixaban128$65,183
JardianceEmpagliflozin76$59,296
ZenpepLipase/Protease/Amylase23$44,143
JanuviaSitagliptin Phosphate50$37,561
CreonLipase/Protease/Amylase22$37,413
FarxigaDapagliflozin Propanediol39$34,967
Lactulose199$29,201
VascepaIcosapent Ethyl53$27,151
RybelsusSemaglutide11$26,454
JanumetSitagliptin Phos/Metformin Hcl36$26,267
Diclofenac Sodium62$25,860
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate13$24,403
JentaduetoLinagliptin/Metformin Hcl25$20,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$957$240,686242 claims
Ardelyx, Inc.Ibsrela$106$84,12027 claims
PfizerEliquis$215$65,183128 claims
AstraZenecaFarxiga, Brilinta$599$49,11455 claims
Novo NordiskRybelsus, Ozempic$158$46,73528 claims
Aimmune Therapeutics, Inc.Zenpep$331$44,14323 claims
GSKBreo Ellipta$28$5,61714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →